KR950701382A - 감쇠된 호흡 합포체 바이러스 백신 조성물(Attenuated respiratory syncytial virus vaccine compositions) - Google Patents

감쇠된 호흡 합포체 바이러스 백신 조성물(Attenuated respiratory syncytial virus vaccine compositions)

Info

Publication number
KR950701382A
KR950701382A KR1019940703740A KR19940703740A KR950701382A KR 950701382 A KR950701382 A KR 950701382A KR 1019940703740 A KR1019940703740 A KR 1019940703740A KR 19940703740 A KR19940703740 A KR 19940703740A KR 950701382 A KR950701382 A KR 950701382A
Authority
KR
South Korea
Prior art keywords
virus
attenuated
rsv
cpts
cold
Prior art date
Application number
KR1019940703740A
Other languages
English (en)
Other versions
KR100257171B1 (ko
Inventor
로버트 머피 브라이언
메릿트 챠노크 로버트
얼 크로우 2세 제임스
코너스 마크
리 쑤 쿠오-홈
로버트 데이비스 알란
데이비드 루벡 마이클
휴 셀링 버나드
Original Assignee
이곤 이. 버그
아메리칸 홈 프로덕츠 코포레이션
로버트 벤슨
더 유나이티드 스테이츠 오브 아메라카 에즈 리프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이곤 이. 버그, 아메리칸 홈 프로덕츠 코포레이션, 로버트 벤슨, 더 유나이티드 스테이츠 오브 아메라카 에즈 리프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 filed Critical 이곤 이. 버그
Publication of KR950701382A publication Critical patent/KR950701382A/ko
Application granted granted Critical
Publication of KR100257171B1 publication Critical patent/KR100257171B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)

Abstract

본 발명은 감쇠된 호흡 하보제 바이러스(RSV)의 백신 조성물을 제공한다. 보다 특정하게, 감쇠된 바이러스는 온도 민감성(ts) 또는 한랭 적응성(ca) 표현형을 갖는 바이러스를 생성시키는 돌연변이를 도입하거나 한랭계대접종시킴으로써 불완전하게 감쇠된 RSV의 유도체일 수 있다. 본 발명은 또한 감쇠된 RSV를 투여함으로써 호흡 합포제 바이러스로부터의 보호를 유발하도록 개체의 면역계를 자극하는 방법을 제공한다. 본 발명은 또한, 이미 불완전하게 감쇠된 ts 또는 cp 돌연변이체로 동정된 바이러스를 추가로 유도체화하여 보다 완전히 감쇠시킨 감쇠된 RS 바이러스의 순수한 배양물을 제공한다.

Description

감쇠된 호흡 합포체 바이러스 백신 조성물(Attenuated respiratory syncytial virus vaccine compositions)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (29)

  1. 숙주 범위 제한되고 (host range-restricted) 한랭 계대접종된(cold-passaged)호흡 합포체 바이러스의 온도 민감성 돌연변이체, 숙주 범위 제한되고 한랭 계대접종된 호흡 합포체 바이러스의 한랭 적응된(cold-adapted) 돌연변이체 또는 추가의 온도 민감성 돌연변이가 이루어진 온도 민감성 호흡 합포체 바이러스 돌연변이체 중에서 선택된, 두 가지 이상의 감쇠 돌연변이가 이루어진 감쇠된 호흡 합포체 바이러스 하나 이상을 생리학적으로 허용되는 담체중에 포함하는 백신 조성물.
  2. 제1항에 있어서, 면역 반응을 향상시키기 위한 보조제를 추가로 포함하는 백신 조성물.
  3. 제1항에 있어서, 바이러스가, 바이러스에게 온도 민감성을 부여하거나 조직 배양물상에 정상적인 크기의 프라크를 생성시킬 수 없도록 하는 하나 이상의 추가의 돌연변이를 도입함으로써 좀더 감쇠된, 숙주 범위 제한되고 한랭 계대접종된 호흡 합포체 바이러스인 백신 조성물.
  4. 제1항에 있어서, 감쇠된 바이러스가, 바이러스를 좀더 감쇠시키고 이에 한랭 적응성을 부여하기 위해 약 20℃ 내지 약 25℃의 온도에서 한랭 계대접종시킨, 숙주 범위 제한되고 한랭 계대접종된 호흡 합포체 바이러스인 백신.
  5. 제1항에 있어서, 감쇠된 바이러스가, 바이러스가 조직 배양물상에 정상적인 크기의 플라크를 생성시킬 수 없게 하거나 추가로 온도 민감성으로 되도록 하는 한랭 계대접종 또는 화학적 돌연변이 유발에 의해 하나 이상의 돌연변이를 도입함으로써 추가로 감쇠된ts-1 NG-1인 백신.
  6. 제5항에 있어서,ts-1 NG-1 바이러스가 하나 이상의 돌연변이를 도입함으로써 추가로 감쇠된 백신.
  7. 제1항에 있어서, 감쇠된 바이러스가, 바이러스가 조직 배양물상에 정상적인 크기의 플라크를 생성시킬 수 없게 하거나 추가로 온도 민감성으로 되도록 하는 한랭 계대접종 또는 화학적 돌연변이 유발에 의해 하나 이상의 돌연변이를 도입함으로써 추가로 감쇠된 -1tsNG-4인 백신.
  8. 제7항에 있어서,ts-4 바이러스가 하나 이상의 돌연변이를 도입함으로써 추가로 감쇠된 백신.
  9. 제1항에 있어서, 감쇠된 바이러스가 아그룹 A 또는 B인 백신.
  10. 제1항에 있어서, 감쇠된 바이러스가 아그룹 A의 A2균주의 바이러스인 백신.
  11. 제1항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404,248/804,248/955,cpts spRSV 248/1228; (ii)cptsRSV 475; (iii)cptsRSV 530,530/9, 530/346, 530/653, 530/667, 530/403, 530/188, 530/464, 530/1009, 530/1178, 530/1074, 530/963,530/977,530/1030,530/1003; (iv)cpRSV 3131 D1; (v)ts-1 NG1/A-20-4, A-37-8, A-15-7, A-25-8, A-21; 및 (vi) RSVts-4/F-15-8, F-19-1, F-20-7, F-29-7, F-31-2의 그룹중에서 선택되는 백신 조성물.
  12. 제1항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404,248/804,248/955,cpts spRSV 248/1228; (ii)cptsRSV 530; (iii)cptsRSV 3131 D1; (iv) RSVts-1 NG1/A-20-4, A-37-8; 및 (v)ts-4/F-19-1, F-29-7의 그룹중에서 선택되는 백신 조성물.
  13. 제1항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404; (ii)cptsRSV 530; (iii) RSVts-1 NG1/A-20-4, A-37-8; 및 (iv)ts-4/F-19-1, F-29-7의 그룹중에서 선택되는 백신 조성물.
  14. 제1항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248/404; (ii)cptsRSV 530; (iii) RSVts-1 NG1/A-20-4 중에서 선택되는 백신 조성물.
  15. 제1항에 있어서, 감쇠된 바이러스 103내지 106PFU의 용량으로 제제화된 백신.
  16. 두가지 이상의 감쇠 돌연변이가 이루어진 숙주 범위 제한되고 한랭 계대접종된 호흡 함포체 바이러스의 온도 민감성 돌연변이체, 숙주 범위제한되고 한랭 계대접종된 호흡 합포체 바이러스의 한랭 적응된 돌연변이체 및 추가의 온도 민감성 돌연변이가 이루어진 온도 민감성 호흡 합포체 바이러스 중에서 선택된 하나 이상의 감쇠된 바이러스를 생리학적으로 허용되는 담체중에서 면역학적 충분량으로 개체에게 투여함을 포함하며, 호흡 합포체 바이러스로부터 보호를 유발하기 위해 개체의 면역계를 자극하는 방법.
  17. 제16항에 있어서, 바이러스가, 바이러스에게 온도 민감성을 부여하거나 조직 배양물상에 정상적인 크기의 플라크를 생성할 수 없도록 하는 두 가지 이상의 돌연변이를 도입함으로써 추가로 감쇠된, 숙주 범위 제한되고 한랭 계대접종된 호흡 합포체 바이러스인 방법.
  18. 제16항에 있어서, 감쇠된 바이러스가, 바이러스를 좀 더 감쇠시키고 한랭 적응성으로 되도록 약 20℃내지 약 25℃의 온도에서 한랭 계대접종시킨, 숙주 범위 제한되고 한랭 계대접종된 호흡 합포체 바이러스인 방법.
  19. 제16항에 있어서, 감쇠된 바이러스가, 바이러스가 조직 배양물상에 정상적인 크기의 플라크를 생성시킬 수 없게 하거나 추가로 온도 민감성으로 되도록 하는 한랭 계대접종 또는 화학적 돌연변이 유발에 의해 하나이상의 돌연변이를 도입함으로써 추가로 감쇠된ts-1 NG-1 또는ts-4인 방법.
  20. 제16항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404,248/804,248/955,cpts spRSV 248/1228; (ii)cptsRSV 475; (iii)cptsRSV 530,530/9, 530/346, 530/653, 530/667, 530/403, 530/188, 530/464, 530/1009, 530/1178, 530/1074, 530/963,530/977,530/1030,530/1003; (iv)cpRSV 3131 D1; (v)ts-1 NG1/A-20-4, A-37-8, A-15-7, A-25-8, A-21; 및 (vi) RSVts-4/F-15-8, F-19-1, F-20-7, F-29-7, F-31-2의 그룹중에서 선택되는 방법.
  21. 제16항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404,248/804,248/955,cpts spRSV 248/1228; (ii)cptsRSV 530; (iii)cptsRSV 3131 D1; (iv) RSVts-1 NG1/A-20-4, A-37-8; 및 (v)ts-4/F-19-1, F-29-7의 그룹중에서 선택되는 방법.
  22. 제16항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248, 248/404; (ii)cptsRSV 530; (iii) RSVts-1 NG1/A-20-4, A-37-8; 및 (iv)ts-4/F-19-1, F-29-7의 그룹중에서 선택되는 백신 조성물.
  23. 제16항에 있어서, 감쇠된 호흡 합포체 바이러스가 (i)cptsRSV 248/404; (ii)cptsRSV 530; (iii) RSVts-1 NG1/A-20-4 중에서 선택되는 백신 조성물.
  24. 제16항에 있어서, 감쇠된 바이러스 103내지 106PFU의 용량으로 제제화된 백신.
  25. 제16항에 있어서, 감쇠된 바이러스 개체의 기도 상부에 투여되는 방법.
  26. 제25항에 있어서, 감쇠된 바이러스가 비인강에 투여되는 방법.
  27. 제25항에 있어서, 감쇠된 바이러스가 스프레이, 비말 또는 에어로졸로서 투여되는 방법.
  28. 제16항에 있어서, 감쇠된 바이러스가 이러한 바이러스에 대한 항체에 대해 혈청음성인 개체에게 투여되는 방법.
  29. 제16항에 있어서, 감쇠된 바이러스가 이러한 바이러스에 대한 혈청양성인 개체에게 투여되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940703740A 1992-04-21 1993-04-20 약독화된 호흡 합포체 바이러스 백신 조성물 KR100257171B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US7/872746 1992-04-21
US7/872,746 1992-04-21
US3994593A 1993-04-09 1993-04-09
US8/039945 1993-04-09
US8/039,945 1993-04-09
PCT/US1993/003670 WO1993021310A1 (en) 1992-04-21 1993-04-20 Attenuated respiratory syncytial virus vaccine compositions

Publications (2)

Publication Number Publication Date
KR950701382A true KR950701382A (ko) 1995-03-23
KR100257171B1 KR100257171B1 (ko) 2000-05-15

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940703740A KR100257171B1 (ko) 1992-04-21 1993-04-20 약독화된 호흡 합포체 바이러스 백신 조성물

Country Status (18)

Country Link
US (3) US5922326A (ko)
EP (1) EP0640128B1 (ko)
JP (1) JP3883202B2 (ko)
KR (1) KR100257171B1 (ko)
AT (1) ATE181359T1 (ko)
AU (1) AU683840B2 (ko)
CA (1) CA2118509C (ko)
DE (1) DE69325370T2 (ko)
DK (1) DK0640128T3 (ko)
ES (1) ES2132233T3 (ko)
GR (1) GR3031208T3 (ko)
HU (1) HU220189B (ko)
IL (1) IL105456A (ko)
MX (1) MX9302278A (ko)
NZ (1) NZ252857A (ko)
RU (1) RU2139729C1 (ko)
UA (1) UA41315C2 (ko)
WO (1) WO1993021310A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (ko) * 1992-04-21 1996-05-11 American Cyanamid Co
AU677090B2 (en) 1993-08-06 1997-04-10 Connaught Laboratories Limited Inactivated respiratory syncytial viral vaccines
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) * 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
EP0917592A4 (en) * 1996-04-04 2002-04-24 Univ Michigan REDUCED RSV
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
CA2260107A1 (en) * 1996-07-12 1998-01-22 The Regents Of The University Of Michigan Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
KR100658491B1 (ko) 1996-07-15 2006-12-18 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 에즈 레프리젠티드 바이 더 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈 클론닝된 뉴클레오타이드 서열로부터 약독화된 호흡기 세포 융합 바이러스 백신의 생산
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CN1232504A (zh) * 1996-09-27 1999-10-20 美国氰胺公司 在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
EP1690940A1 (en) 1999-04-13 2006-08-16 The Government of the United States of America as Represented by The Department of Health and Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
BR0013195A (pt) * 1999-07-09 2002-07-23 Government Of The Us Dept Of H Produção de vacinas de virus sincicial respiratório quimérico humano-bovino, atenuado
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
JP2003528925A (ja) 2000-04-03 2003-09-30 ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション 低温適応型ウマインフルエンザウイルス
US7118888B2 (en) * 2001-09-28 2006-10-10 University Of South Florida Board Of Trustees Gene expression vaccine
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP2005523698A (ja) 2002-04-26 2005-08-11 メディミューン・ヴァクシンズ・インコーポレーテッド インフルエンザウイルスの生産用多重プラスミドシステム
WO2004028478A2 (en) * 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
WO2004083397A2 (en) * 2003-03-18 2004-09-30 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
ATE469170T1 (de) * 2003-03-28 2010-06-15 Medimmune Llc Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
CA2816222A1 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
EP1697521B1 (en) 2003-12-23 2010-06-02 MedImmune, LLC Multi plasmid system for the production of influenza virus
ES2454266T3 (es) * 2004-05-25 2014-04-10 Medimmune, Llc Variantes de la hemaglutinina y la neuraminidasa de influenza
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
WO2008133701A1 (en) * 2006-07-21 2008-11-06 Medimmune, Llc. Methods and compositions for increasing replication capacity of an influenza virus
CN101983069B (zh) 2006-08-09 2014-07-16 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
JP5666905B2 (ja) * 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
AU2009268576B2 (en) * 2008-07-11 2014-03-27 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
EP2764015A1 (en) 2011-10-07 2014-08-13 Medlmmune, LLC Influenza hemagglutinin variants
PL3511015T3 (pl) 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
AU2014236340B2 (en) 2013-03-14 2019-01-17 Massachusetts Institute Of Technology Nanoparticle-based compositions
WO2014152534A1 (en) 2013-03-14 2014-09-25 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
JP7311872B2 (ja) 2015-10-29 2023-07-20 エモリー ユニバーシティー キメラｒｓｖ、免疫原性組成物、及び使用方法
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
EP0640128A1 (en) 1995-03-01
HUT69992A (en) 1995-09-28
NZ252857A (en) 1997-06-24
IL105456A (en) 1996-12-05
RU94045898A (ru) 1996-09-20
MX9302278A (es) 1994-07-29
GR3031208T3 (en) 1999-12-31
KR100257171B1 (ko) 2000-05-15
US5882651A (en) 1999-03-16
WO1993021310A1 (en) 1993-10-28
EP0640128B1 (en) 1999-06-16
AU4290793A (en) 1993-11-18
US5922326A (en) 1999-07-13
ATE181359T1 (de) 1999-07-15
DE69325370T2 (de) 1999-10-14
CA2118509C (en) 2009-05-19
DK0640128T3 (da) 1999-11-22
UA41315C2 (uk) 2001-09-17
IL105456A0 (en) 1993-08-18
RU2139729C1 (ru) 1999-10-20
DE69325370D1 (de) 1999-07-22
ES2132233T3 (es) 1999-08-16
JPH07505891A (ja) 1995-06-29
JP3883202B2 (ja) 2007-02-21
AU683840B2 (en) 1997-11-27
US6284254B1 (en) 2001-09-04
HU9403023D0 (en) 1994-12-28
HU220189B (hu) 2001-11-28
CA2118509A1 (en) 1993-10-28

Similar Documents

Publication Publication Date Title
KR950701382A (ko) 감쇠된 호흡 합포체 바이러스 백신 조성물(Attenuated respiratory syncytial virus vaccine compositions)
Jungeblut et al. Studies of a murine strain of poliomyelitis virus in cotton rats and white mice
DE69827779T2 (de) Detoxifizierte mutanten bakterieller adp-ribosylierender toxine als parenterale adjuvantien
Holder et al. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies
DE69225471T2 (de) Abgeschwächtes, gentechnologisch hergestelltes pseudorabies virus s-prv-155 und seine verwendungen
CA2339089A1 (en) Cold-adapted equine influenza viruses
CA1204056A (en) Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
DE69333028D1 (de) Deletionsmutanten als impfstoffe gegen cholera
WO2001060849A3 (en) Cold-adapted equine influenza viruses
CA2086097A1 (en) Adjuvants and vaccines
Hearn Jr et al. Cross-protection in animals infected with group A arboviruses
EP1323428A3 (en) Avirulent Salmonella typhi microbes and uses thereof
Fox Modes of action of poliovirus vaccines and relation to resulting immunity
US4008317A (en) Varicella-zoster virus vaccine and preparation thereof
Milzer et al. A new method for the production of potent inactivated vaccines with ultraviolet irradiation: III. A completely inactivated poliomyelitis vaccine with the lansing strain in mice
Grayston Immunization against trachoma
CA2224309A1 (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
HU228401B1 (en) Smallpox vaccine
CA2222482A1 (en) Non-virulent mycoplasma synoviae and vaccine thereof
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
MXPA02011654A (es) Composicion de vacuna.
Ki-Man et al. Cytokine and antibody responses of reactivated murine toxoplasmosis upon administration of dexamethasone
SU546132A1 (ru) Способ профилактики гриппа
Reuman et al. Childhood immunization update
Preston et al. Toxoid vaccine for pertussis

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060224

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee